New molecular diagnostic test for prostate cancer.

From the early nineties, death from prostate cancer was reduced by 50%, thanks to new ways to treat cancer and hormone therapy, radical surgery or radiotherapy, y al uso de herramientas de diagnóstico precoz como el test PSA.

The PSA test was discovered in 1980 by Dr. Chu observing the levels of this protein in the blood of patients. In 1986 The test was approved by the FDA to monitor response to treatment but it was not until 1994 when it was adopted as a diagnostic tool.
Antes del test PSA, solo el 4% Men with prostate cancer were cured and had a high percentage and bone metastases at the time of screening. The standard treatment was hormone androgen blockade and the median survival was 3 years old.
Con el desarrollo del test PSA se cambió la capacidad de diagnóstico, menos del 10% of patients diagnosed with prostate cancer have an incurable tumor today and survival 5 years is, 99.2%
The incidence of prostate cancer is very high. 20% of young people 20 years and evidence has prostate cancer and 80% of men over 80 years have Prostate Cancer.
The use of the PSA test is some controversy about the high risk of overdiagnosis and overtreatment as the inability to detect a significant proportion of aggressive tumors.
So are developing new molecular test that together with the PSA that are more accurate in the early diagnosis and monitoring of disease. One is a urine test that determines the levels of antigen 3 prostate cancer (PCA3 o DD3) in this fluid. Have an increased susceptibility to the PSA. It is being used in conjunction with the PSA test. PCA3 is an antisense mRNA overexpressed in more than 95% prostate tumors Degree.
Este nuevo test de diagnóstico molecular se está estableciendo en la práctica diaria en hospitales españoles, permitiendo acortar los tiempos para la obtención de resultados con la mejor calidad de respuesta.